US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at -0.19 against a street estimate of 0.13 — a miss of 246.2%.
Analysts rate Hims Hers Health Inc a hold (5 buy, 6 hold, 2 sell out of 13) with an average price target of $29.23.
| Fund | Stake |
|---|---|
| BlackRock Inc | 11.38% |
| Vanguard Portfolio Management, LLC | 4.40% |
| Vanguard Capital Management, LLC | 4.04% |
| Morgan Stanley - Brokerage Accounts | 3.84% |
| State Street Corp | 3.22% |
| Defiance ETFs, LLC | 3.21% |
| JPMorgan Chase & Co | 2.26% |
| Geode Capital Management, LLC | 2.25% |
| Document | Date |
|---|---|
| Board / officer change · Q3 2026 | 2026-07-17 |
| Material agreement · Q2 2026 | 2026-07-01 |
| Shareholder vote results · Q2 2026 | 2026-06-15 |
| Material agreement · Q2 2026 | 2026-06-02 |
| Quarterly report · Q1 2026 | 2026-05-11 |
| Proxy statement · Q2 2026 | 2026-04-28 |
| Annual report FY2025 | 2026-02-23 |
| Quarterly report · Q3 2025 | 2025-11-03 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Hims Hers Health Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.